LILRB4 (NGM-831 Biosimilar) Recombinant Monoclonal Antibody

Code CSB-RA850914MB4HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
NGM 831 research-grade biosimilar; NGM-831 research-grade biosimilar ;LILRB4 antibody; ILT3 antibody; LIR5 antibody; Leukocyte immunoglobulin-like receptor subfamily B member 4 antibody; B4 antibody; CD85 antigen-like family member K antibody; Immunoglobulin-like transcript 3 antibody; ILT-3 antibody; Leukocyte immunoglobulin-like receptor 5 antibody; LIR-5 antibody; Monocyte inhibitory receptor HM18 antibody; CD antigen CD85k antibody
Species Reactivity
Human
Immunogen
Recombinant Human LILRB4 protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS,pH7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
3-4 weeks
Description

This recombinant monoclonal antibody is developed as a research-grade biosimilar to NGM-831, targeting LILRB4 (Leukocyte Immunoglobulin-Like Receptor B4), an inhibitory immune checkpoint receptor predominantly expressed on myeloid cells including monocytes, macrophages, and dendritic cells. LILRB4 functions as a critical regulator of immune responses by delivering inhibitory signals upon ligand binding, thereby suppressing myeloid cell activation and antigen presentation. This receptor plays a significant role in immune evasion mechanisms in various malignancies, particularly acute myeloid leukemia (AML), where it is frequently overexpressed on leukemic blasts and contributes to tumor immune escape by impairing anti-tumor immunity.

NGM-831 is an investigational therapeutic antibody designed to block LILRB4 function, thereby enhancing myeloid cell-mediated immune responses against cancer cells. This biosimilar provides researchers with a valuable tool for investigating LILRB4-mediated immunosuppression, studying myeloid checkpoint biology, and exploring therapeutic strategies targeting the tumor microenvironment. It supports studies in immuno-oncology, myeloid biology, and immune checkpoint regulation across hematologic and solid tumor models.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. Involved in the down-regulation of the immune response and the development of tolerance, e.g. towards transplants. Interferes with TNFRSF5-signaling and NF-kappa-B up-regulation. Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.
Gene References into Functions
  1. Results suggest that ILT3 played an important role in tumor progression in colorectal cancer by possible influence on CD45RO+ T cells in the tumor microenvironment. PMID: 30126665
  2. These results suggest that tyrosine phosphorylation may be critical in FcgammaRI-dependent endocytosis/phagocytosis that may be regulated by LILRB4 by triggering dephosphorylation of key signalling proteins. PMID: 27725776
  3. ILT3 may functionally contribute to a regulatory network controlling tumor progression by suppressing the Akt pathway. PMID: 28931525
  4. The ILT3 PBs/PCs were suggested to be developmentally equivalent based on the simultaneous generation of these populations upon activation of memory B cells in vitro ILT3 expression was found to be induced efficiently by IL-2, while IFN-alpha effectively induced ILT3 PBs/PCs in vitro Utilizing the elevated ILT3 will support opening a new avenue for molecular markers for, pathogenic cells. PMID: 27742834
  5. this study shows that LILRB4 might have dual inhibitory and activating functions, depending on the position of the functional tyrosine residues in its immunoreceptor tyrosine-based inhibitory motifs and/or the nature of the stimuli PMID: 28409541
  6. LILRB4 expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
  7. Identification of ILT4 as a cellular receptor for CSP C4d PMID: 26678451
  8. ILT3Fc inhibits T cell activation and induces the generation of suppressor T cells targeting multiple inflammatory miRNA pathways. PMID: 22387553
  9. Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3/LIR-5/CD85k): a myeloid inhibitory receptor involved in immune tolerance. PMID: 21454581
  10. Data show that LILRB4 is a potent inhibitor of monocyte activation via FcgammaRI. PMID: 19833736
  11. ILT3 precursor RNA is expressed and retained in nuclei of resting endothelial cells. PMID: 16433759
  12. Our findings indicate that expression of ILT3 and ILT4 on CLL B cells represents a phenotypic abnormality that may play a role in tolerization of tumor-specific T cells. PMID: 17266150
  13. The inhibitory effect of serum and membrane ILT3 in a humanized SCID mouse model describes an immune-escape mechanism that could contribute to impaired T cell responses in patients with cancer. PMID: 17513794
  14. Both membrane and soluble ILT3 are proteins with potent immunosuppressive activity which are of importance for treatment of rejection, autoimmunity and cancer. PMID: 17923119
  15. describe an immune-escape mechanism mediated by the inhibitory receptor immunoglobulin-like transcript 3 (ILT3) which may be responsible for failure of pancreatic cancer therapy PMID: 17993722
  16. Progenitor mast cells expressed cell surface inhibitory LILRB4. Mature cord-blood-derived mast cells had detectable mRNA encoding multiple LILRs, none were expressed on the cell surface. PMID: 17998301
  17. ILT3-Fc is a potent immunoregulatory agent that suppresses islet allograft rejection in humanized NOD/SCID mice. PMID: 18420485
  18. 15 single nucleotide polymorphisms are identified in the extracellular domain of immunoglobulin-like transcript 3 gene from healthy individuals. PMID: 18486764
  19. Expressed on cultured osteoclast precursor cells derived from peripheral blood monocytes; could be inhibitory for osteoclast development in presence of receptor activator of NF-kappaB ligand (RANKL) and macrophage colony stimulating factor (M-CSF). PMID: 18802077
  20. A significant association is observed between ILT3 dendritic cells in kidney transplants and donor age. PMID: 19010139
  21. ILT3 may play a critical role in the control of inflammation. PMID: 19380766
  22. A tryptophan-deprived environment generates monocyte-derived dendritic cells with a marked up-regulation of inhibitory receptors ILT3 and ILT4 and enhanced capacity to induce CD4+CD25+Foxp3+ regulatory T cells in an ILT3-dependent manner. PMID: 19535644

Show More

Hide All

Subcellular Location
Cell membrane; Single-pass type I membrane protein. Note=Ligand binding leads to internalization and translocation to an antigen-processing compartment.
Tissue Specificity
Detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells.
Database Links

HGNC: 6608

OMIM: 604821

KEGG: hsa:11006

STRING: 9606.ENSP00000270452

UniGene: Hs.67846

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*